Article: Integrating molecular mechanisms and clinical evidence in the management of Trastuzumab resistant or refractory Her-2 + metastatic breast cancer

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleIntegrating molecular mechanisms and clinical evidence in the management of Trastuzumab resistant or refractory Her-2 + metastatic breast cancer
AuthorsWong, H
Leung, R
Kwong, A
Chiu, J
Liang, R
Swanton, C
Yau, T
KeywordsAKT
Breast cancer
ErbB-2
mTOR
PI3 kinase
Trastuzumab
Issue Date2011
PublisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/
CitationOncologist, 2011, v. 16 n. 11, p. 1535-1546 [How to Cite?]
DOI: http://dx.doi.org/10.1634/theoncologist.2011-0165
AbstractHuman epidermal growth factor receptor (HER)-2 + breast cancer is a distinct molecular and clinical entity, the prognosis of which is improved by trastuzumab. However, primary resistance to Trastuzumab is observed in >50% of patients with HER-2 + advanced breast cancer, and the majority of patients who initially respond to treatment eventually develop disease progression. To facilitate crosstrial comparisons and the understanding of resistance mechanisms, we propose a unifying definition of trastuzumab resistance as progression at first radiological reassessment at 8-12 weeks or within 3 months after first-line trastuzumab in the metastatic setting or new recurrences diagnosed during or within 12 months after adjuvant trastuzumab. In contrast, we define trastuzumab-refractory breast cancer as disease progression after two or more lines of Trastuzumab-containing regimens that initially achieved disease response or stabilization at first radiological assessment. We review mechanisms of trastuzumab resistance mediated by p95HER-2 overexpression, phosphoinositide 3-kinase pathway activation, and signaling pathway activation driven by HER-3, epidermal growth factor receptor, and insulin-like growth factor 1 receptor. We distinguish in vitro from in vivo evidence, highlighting that most data describing trastuzumab resistance are derived from preclinical studies or small retrospective patient cohorts, and discuss targeted therapeutic approaches to overcome resistance. Prospective analysis through clinical trials with robust tissue collection procedures, prior to and following acquisition of resistance, integrated with next-generation tumor genome sequencing technologies, is identified as a priority area for development. The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies. © AlphaMed Press.
ISSN1083-7159
2011 Impact Factor: 3.91
2011 SCImago Journal Rankings: 0.460
DOIhttp://dx.doi.org/10.1634/theoncologist.2011-0165
ISI Accession Number IDWOS:000297860900008
Funding AgencyGrant Number
Raymond Liang
Funding Information:

Raymond Liang

PubMed Central IDPMC3233287
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorWong, H
dc.contributor.authorLeung, R
dc.contributor.authorKwong, A
dc.contributor.authorChiu, J
dc.contributor.authorLiang, R
dc.contributor.authorSwanton, C
dc.contributor.authorYau, T
dc.date.accessioned2012-09-05T05:31:13Z
dc.date.available2012-09-05T05:31:13Z
dc.date.issued2011
dc.description.abstractHuman epidermal growth factor receptor (HER)-2 + breast cancer is a distinct molecular and clinical entity, the prognosis of which is improved by trastuzumab. However, primary resistance to Trastuzumab is observed in >50% of patients with HER-2 + advanced breast cancer, and the majority of patients who initially respond to treatment eventually develop disease progression. To facilitate crosstrial comparisons and the understanding of resistance mechanisms, we propose a unifying definition of trastuzumab resistance as progression at first radiological reassessment at 8-12 weeks or within 3 months after first-line trastuzumab in the metastatic setting or new recurrences diagnosed during or within 12 months after adjuvant trastuzumab. In contrast, we define trastuzumab-refractory breast cancer as disease progression after two or more lines of Trastuzumab-containing regimens that initially achieved disease response or stabilization at first radiological assessment. We review mechanisms of trastuzumab resistance mediated by p95HER-2 overexpression, phosphoinositide 3-kinase pathway activation, and signaling pathway activation driven by HER-3, epidermal growth factor receptor, and insulin-like growth factor 1 receptor. We distinguish in vitro from in vivo evidence, highlighting that most data describing trastuzumab resistance are derived from preclinical studies or small retrospective patient cohorts, and discuss targeted therapeutic approaches to overcome resistance. Prospective analysis through clinical trials with robust tissue collection procedures, prior to and following acquisition of resistance, integrated with next-generation tumor genome sequencing technologies, is identified as a priority area for development. The identification of predictive biomarkers is of paramount importance to optimize health economic costs and enhance stratification of anti-HER-2 targeted therapies. © AlphaMed Press.
dc.description.natureLink_to_OA_fulltext
dc.identifier.citationOncologist, 2011, v. 16 n. 11, p. 1535-1546 [How to Cite?]
DOI: http://dx.doi.org/10.1634/theoncologist.2011-0165
dc.identifier.doihttp://dx.doi.org/10.1634/theoncologist.2011-0165
dc.identifier.epage1546
dc.identifier.hkuros198374
dc.identifier.isiWOS:000297860900008
Funding AgencyGrant Number
Raymond Liang
Funding Information:

Raymond Liang

dc.identifier.issn1083-7159
2011 Impact Factor: 3.91
2011 SCImago Journal Rankings: 0.460
dc.identifier.issue11
dc.identifier.pmcidPMC3233287
dc.identifier.pmid22020213
dc.identifier.scopuseid_2-s2.0-82355164794
dc.identifier.spage1535
dc.identifier.urihttp://hdl.handle.net/10722/163425
dc.identifier.volume16
dc.languageeng
dc.publisherAlphaMed Press, Inc. The Journal's web site is located at http://www.theoncologist.org/
dc.publisher.placeUnited States
dc.relation.ispartofOncologist
dc.relation.referencesReferences in Scopus
dc.subject.meshAntibodies, Monoclonal, Humanized - Pharmacology
dc.subject.meshAntineoplastic Agents - Pharmacology
dc.subject.meshBreast Neoplasms - Drug Therapy - Enzymology - Genetics - Pathology
dc.subject.meshDrug Resistance, Neoplasm
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshNeoplasm Metastasis
dc.subject.meshProspective Studies
dc.subject.meshReceptor, Erbb-2 - Antagonists & Inhibitors - Biosynthesis - Genetics - Metabolism
dc.subjectAKT
dc.subjectBreast cancer
dc.subjectErbB-2
dc.subjectmTOR
dc.subjectPI3 kinase
dc.subjectTrastuzumab
dc.titleIntegrating molecular mechanisms and clinical evidence in the management of Trastuzumab resistant or refractory Her-2 + metastatic breast cancer
dc.typeArticle
Author Affiliations
  1. CRUK London Research Institute
  2. The University of Hong Kong
  3. Royal Marsden Hospital, Sutton